局限期小细胞肺癌胸部精确放疗的网状<i>Meta分析</i>

doi:10.3760/cma.j.cn113030-20210922-00365

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To systematically evaluate the efficacy and safety of precision thoracic radiotherapy (TRT) in the limited-stage small cell lung cancer (LS-SCLC) patients by network meta-analysis. Methods Randomized controlled trials (RCTs) of TRT regimes in the LS-SCLC were electronically searched from PubMed, Web of Science, The Cochrane Library, CNKI and Wanfang Data from inception to September 1^st, 2021. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Statistical analysis was performed by Stata 17 and R 4.1.1software. Results A total of 6 RCTs involving 1730 patients with six radiation regimens including hyperfractionated radiotherapy (HFRT):HFRT₄₅(45Gy/30 F) and HFRT₆₀(60Gy/40 F);conventional fractionated radiotherapy (CFRT):CFRT₇₀(70Gy/35 F) and CFRT₆₆(66Gy/33 F);moderately hypofractionated radiotherapy (MHFRT):MHFRT₆₅(65Gy/26 F) and MHFRT₄₂(42Gy/15 F) were included. The network meta-analysis showed that:in terms of improving progression-free survival and overall survival, there was no statistically significant difference among the six radiotherapy regimens. The probabilistic ranking results were:MHFRT₆₅ > HFRT₆₀ > CFRT₆₆ > CFRT₇₀ > MHFRT₄₂ > HFRT₄₅, and HFRT₆₀ > MHFRT₆₅ > CFRT₆₆ > CFRT₇₀ > HFRT₄₅ > MHFRT₄₂, respectively. The HFRT₆₀ regimen was superior to other regimens in reducing the incidence of grade ≥3 pneumonia, and there was no difference between the regimens in causing grade ≥3 radiation esophagitis, and the results of ranking probability were:HFRT₆₀ > MHFRT₄₂ > CFRT₆₆ > CFRT₇₀ > HFRT₄₅ > MHFRT₆₅, and HFRT₆₀ > CFRT₇₀ > CFRT₆₆ > HFRT₄₅ > MHFRT₄₂ > MHFRT₆₅, respectively. Conclusions HFRT₆₀ radiotherapy regimen may be more effective and safer in the treatment of LS-SCLC patients as a priority choice for LS-SCLC TRT. Limited by the number and quality of included studies, the above conclusions need to be verified by more high-quality studies.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yang Tao
	Cao Lijuan
	Jiang Xiaodong
	Fan Yuwei
	Li Jia
	Wu Dan
	Chen Hanbo
	Xia Youyou

Key words： Limited-stage Carcinoma, small cell lung Radiotherapy Prognosis Network meta-analysis

Received: 22 September 2021

Fund:Wu Jieping Medical Fund Project (320.6750.2020-10-73)

Corresponding Authors: Xia Youyou, Email:read767@163.com

Cite this article:

Yang Tao,Cao Lijuan,Jiang Xiaodong et al. Precision thoracic radiotherapy in limited-stage small cell lung cancer:a network meta-analysis[J]. Chinese Journal of Radiation Oncology, 2022, 31(5): 431-437.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20210922-00365 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I5/431

[1] Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality[J]. N Engl J Med, 2020, 383(7):640-649. DOI:10.1056/NEJMoa1916623.
[2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33. DOI:10.3322/caac.21654.
[3] 中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会, 中国抗癌协会放射治疗专业委员会, 等. 中国小细胞肺癌放射治疗临床指南(2020版)[J]. 中华放射肿瘤学杂志, 2020, 29(8):608-614. DOI:10.3760/cma.j.cn113030-20200528-00285.
Clinical practice guideline for radiation therapy in small cell lung cancer (2020 version)[J]. Chinese Journal of Radiation Oncology,2020,29(8):608-614. DOI:10.3760/cma.j.cn113030-20200528-00285.
[4] Nicholson AG, Chansky K, Crowley J, et al. The international association for the study of lung cancer lung cancer staging project:proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(3):300-311. DOI:10.1016/j.jtho.2015.10.008.
[5] 中国临床肿瘤学会指南工作委员会. 小细胞肺癌诊疗指南(2020版)[M]. 北京:人民卫生出版社,2020.
Chinese Society of Clinical Oncology Guidelines Committee. Clinical Practice Guidelines for diagnosis treatment and follow-up in small cell lung cancer (2020 version)[M]. Beijing:People's Medical Publishing House,2020.
[6] Colaco R, Sheikh H, Lorigan P, et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer—evidence from a phase Ⅱ trial[J]. Lung Cancer, 2012, 76(1):72-77. DOI:10.1016/j.lungcan.2011.09.015.
[7] Grønberg BH, Halvorsen TO, FløttenØn,et al. Randomized phase Ⅱ trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer[J]. Acta Oncol, 2016, 55(5):591-597. DOI:10.3109/0284186X.2015.1092584.
[8] Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label, phase 3, randomised, superiority trial[J]. Lancet Oncol, 2017, 18(8):1116-1125. DOI:10.1016/S1470-2045(17)30318-2.
[9] Grønberg BH, Killingberg KT,FløttenØn,et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer:an open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2021, 22(3):321-331. DOI:10.1016/S1470-2045(20)30742-7.
[10] Qiu B, Li Q, Liu J, et al. Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer:A multicenter, phase Ⅱ, randomized trial[J]. Int J Radiat Oncol Biol Phys, 2021, 111(2):424-435. DOI:10.1016/j.ijrobp.2021.05.003.
[11] Jeffrey AB, Wang XF, Gregory AM, et al. Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC):CALGB 30610(Alliance)/RTOG 0538[J]. J Clin Oncol,2021,39(suppl 15):8505.
[12] De Ruysscher D, Lueza B, Le Péchoux C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J]. Ann Oncol, 2016, 27(10):1818-1828. DOI:10.1093/annonc/mdw263.
[13] Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med, 1999, 340(4):265-271. DOI:10.1056/NEJM199901283400403.
[14] Xia B, Hong LZ, Cai XW, et al. Phase 2study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 91(3):517-523. DOI:10.1016/j.ijrobp.2014.09.042.
[15] Wang K, Tepper JE. Radiation therapy-associated toxicity:etiology, management, and prevention[J]. CA Cancer J Clin, 2021, 71(5):437-454. DOI:10.3322/caac.21689.
[16] Farrell MJ, Yahya JB, Degnin C, et al. Radiation dose and fractionation for limited-stage small-cell lung cancer:survey of US radiation oncologists on practice patterns[J]. Clin Lung Cancer, 2019, 20(1):13-19. DOI:10.1016/j.cllc.2018.08.015.